Table 1

Patient clinical characteristics

Patient Age (year), gender Germline status Tumor profile Number of prior lines of chemotherapy Metastatic sites at ICI initiation ICI First and last infusion of ICI Reason of ICI discontinuation Overall best response Best response of adrenal gland metastasis PD of adrenal gland metastasis (date) Treatment of adrenal gland progression (date) PD on other metastatic sites (date) The last follow-up visit (status)
#161, FSporadic caseMSI,
MLH1-neg,
BRAFmt
1Liver,
lymph nodes
Anti-PD1 +anti-CTLA406/2015 to 07/2015Necrotizing myositisPRNA (not present at baseline)03/2016Adrenalectomy (08/2016)No07/2020 (free of progression)
#244, MLynch syndromeMSI,
MSH2-neg, RAS/RAF-wt
2Adrenal gland
liver,
lymph nodes,
Anti-PD1 +anti-CTLA405/2016 to 03/2018PD (adrenal gland)PRSD03/2018SBRT (06/2018)No06/2020 (free of progression)
#345, MLynch syndromeMSI,
MSH2-neg, KRAS-mt
3Adrenal gland
liver,
lymph nodes
Anti-PD1 +anti-CTLA409/2016 to 11/2019PD (adrenal gland)PRSD12/2019SBRT (03/2020)No06/2020 (free of progression)
#452, MLynch syndromeMSI
MSH6-neg
MSH6-neg
0PeritoneumAnti-PD107/2017
To 02/2019
Grade 3 colitisCRNA (not present at baseline)12/2019Adrenalectomy (03/2020)No06/2020 (free of progression)
#577, FUnknownMLH1-neg
PMS2-neg
╬▓catenine-mt
3Lung,
lymph nodes
Anti-PD1 +anti-CTLA401/2019 To
01/2020
PD (adrenal gland)SDNA (not present at baseline)12/2019Adrenalectomy (03/2020)No06/2020 (free of progression)
  • CR, complete response; ICI, immune checkpoint inhibitor; MSI, microsatellite instability; mt, mutated; neg, negative; PD, progressive disease; PR, partial response; SBRT, stereotactic body radiation therapy; SD, stable disease; wt, wild type.